RARE - Ultragenyx Pharmaceutical Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$48.36
DETAILS
HIGH:
$67.00
LOW:
$26.00
MEDIAN:
$45.00
CONSENSUS:
$48.36
UPSIDE:
106.76%
Profitability Ratios
| Ratio | Value |
|---|---|
| GP Margin | 83.8% |
| EBIT Margin | -79.5% |
| EBITDA Margin | -74.3% |
| Operating Margin | -79.5% |
| Pretax Margin | -84.8% |
| Cont. Ops Margin | -85.4% |
| Net Margin | -85.4% |
| Bottom Line Margin | -85.4% |
Liquidity Ratios
| Ratio | Value |
|---|---|
| Current Ratio | 2.48 |
| Quick Ratio | 2.34 |
| Solvency Ratio | -0.336 |
| Cash Ratio | 1.13 |
Valuation Ratios
| Ratio | Value |
|---|---|
| Price/Earnings |
-3.94
Peers avg: 19.3
|
| PEG Ratio | 0.54 |
| Forward PEG | 0.54 |
| Price/Book | -28.35 |
| Price/Sales | 3.37 |
| Price/FCF | -4.80 |
| Price/Op Cash Flow | -4.87 |
Debt Ratios
| Ratio | Value |
|---|---|
| Debt/Assets | 0.8329 |
| Debt/Equity | -15.9500 |
| Debt/Capital | 1.0669 |
| Long-Term Debt/Capital | 1.0733 |
| Financial Leverage | -19.15 |
Cash Flow Ratios
| Ratio | Value |
|---|---|
| Working Capital Turnover | 1.29 |
| Operating Cash Flow Ratio | -1.214 |
| Operating Cash Flow/Sales | -69.2% |
| Free Cash Flow/Operating Cash Flow | 101.3% |
Coverage Ratios
| Ratio | Value |
|---|---|
| Debt Service Coverage | -3.52 |
| Interest Coverage | -8.6290 |
| Short-Term Operating Cash Flow Coverage | -5.75 |
| Operating Cash Flow Coverage | -0.37 |
| Capital Expenditure Coverage | -77.67 |
| Dividend + Capital Expenditure Coverage | -77.67 |
Dividend Ratios
| Ratio | Value |
|---|---|
| Payout Ratio | 0.0000% |
| Dividend Yield | 0.0000% |
| Dividend Yield % | 0.0000% |
| Dividend Per Share | 0.0000 |
Per Share Ratios
| Ratio | Value |
|---|---|
| Revenue/Share | 6.83 |
| EPS | -5.832 |
| Debt/Share | 13.5700 |
| Cash/Share | 7.03 |
| Book Value/Share | -0.74 |
| Tangible BV/Share | -2.97 |
| Equity/Share | -0.81 |
| Operating Cash Flow/Share | -4.726 |
| Capital Expenditure/Share | 0.061 |
| FCF/Share | -4.787 |
Other Ratios
| Ratio | Value |
|---|---|
| Net Income/Earnings Before Tax | 1.007 |
| Earnings Before Tax/EBIT | 1.067 |
| Price/Fair Value | -28.35 |
| Debt/Market Cap | 0.5521 |
| Effective Tax Rate | -0.7% |
| Enterprise Value Multiple | -6.22 |